Share in our success

Developing and providing safe and effective biopharmaceuticals for unmet medical needs is our first priority. AMIVAS is focused on developing drug products for human use. Our extensive experience in drug development, regulatory processes, and in-licensing, enables us to navigate the complex process of providing consistent and high standard products to protect patient safety.

AMIVAS has demonstrated a successful track record by registering Artesunate for the treatment of severe malaria through the U.S. Food and Drug Administration (FDA), United Kingdom Medicines & Healthcare Products Regulatory Agency (MHRA), and the European Medicines Agency (EMA).

We are interested in connecting with potential partners who want to bring drugs against life-threatening diseases to market in the United States and other jurisdictions.